title: Disturbed LDL and scavenger receptor functions in monocytes from chronic haemodialysed patients.
abstract: BACKGROUND
  The most frequent complication in patients with end-stage renal failure on chronic haemodialysis (HD) treatment is atherosclerosis, i.e. the different forms of heart and vascular diseases. The complete disorder of serum lipid and lipoprotein patterns is well demonstrated, whereas our knowledge about the low-density lipoprotein (LDL) and scavenger receptor expression and function are poorly understood.
  
  
  METHODS
  In our current work, LDL and scavenger receptor expression and functions were simultaneously studied in monocytes obtained from 15 healthy male control subjects and from 11 chronic HD male patients applied with (125)I-labelled LDL, isolated from healthy volunteers. To study the scavenger LDL receptors, labelled acetylated LDL (acLDL) was used.
  
  
  RESULTS
  LDL binding to the monocytes of the HD-group was found to be decreased in comparison to that of the controls. As a result, the 50 microg LDL protein-induced inhibition of endogenous cholesterol synthesis was also diminished. In contrast, acLDL binding was greatly increased, though it could trigger only a low apoE synthesis. Consequently the number of cholesterol inclusions in monocytes was increased.
  
  
  CONCLUSIONS
  The disturbed expression and function of LDL and scavenger receptors both may play significant roles in pathogenesis of cardiovascular complications in chronic HD patients. Based on our present results, it can be assumed that dysfunction of scavenger receptors is at the centre of cardiovascular complications of HD patients with renal failure.
authors.affiliation: First Department of Medicine and Central Research Laboratory, University Medical School of Debrecen, Debrecen, Hungary.
authors.forename: I
authors.initials: I
authors.lastname: Kárpáti
authors.forename: G
authors.initials: G
authors.lastname: Paragh
authors.forename: E
authors.initials: E
authors.lastname: Kovács
authors.forename: Z
authors.initials: Z
authors.lastname: Balogh
authors.forename: M
authors.initials: M
authors.lastname: Szabolcs
authors.forename: J
authors.initials: J
authors.lastname: Szabó
authors.forename: G
authors.initials: G
authors.lastname: Kakuk
authors.forename: G
authors.initials: G
authors.lastname: Fóris
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D011971:Receptors, Immunologic / Q000097:blood*; D011973:Receptors, LDL / Q000097:blood*; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D012016:Reference Values; D006435:Renal Dialysis; D051122:Scavenger Receptors, Class B; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D008077:Lipoproteins, LDL; D008565:Membrane Proteins; D011971:Receptors, Immunologic; D011973:Receptors, LDL; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; C032629:acetyl-LDL; D002784:Cholesterol